24 results on '"Aljumaily, Raid"'
Search Results
2. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
3. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
4. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
5. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
6. Comparing the rate of immunotherapy treatment change due to toxicity by sex
7. A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
8. Abstract CT163: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small cell carcinoma of the ovary, hypercalcemic type cohort
9. Factors Affecting Natural Killer Cell Recovery after Autologous Stem Cell Transplantation in Multiple Myeloma
10. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients withPIK3CA-Mutant Cancers
11. Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
12. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
13. Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
14. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
15. A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors
16. Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)
17. Immunologic and objective tumor responses to PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)
18. P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
19. O3-2-5 - A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors
20. O-004 - Immunologic and objective tumor responses to PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)
21. Selective Blockade of Matrix Metalloprotease-14 with a Monoclonal Antibody Abrogates Invasion, Angiogenesis, and Tumor Growth in Ovarian Cancer
22. Neoadjuvant chemotherapy in the setting of locally advanced olfactory neuroblastoma with intracranial extension
23. Validation of a Pretransplantation Assessment of Mortality (PAM) Score for Predicting Risk of Death in the First Two Years after Allogeneic Hematopoietic Cell Transplantation in a Tertiary Transplant Center.
24. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.